321432-05-7

Basic information

• Product Name: 4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE
• Synonyms: ASISCHEM N48007;4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZALDEHYDE;4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE;4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENE-CARBOXALDEHYDE;ZERENEX E/4048006;2-[(4-Fluorobenzyl)oxy]-5-formylanisole, 1-Fluoro-4-[(4-formyl-2-methoxyphenoxy)methyl]benzene;4-[(4-fluorophenyl)methoxy]-3-methoxybenzaldehyde;4-[(4-fluorophenyl)methoxy]-3-methoxy-benzaldehyde
• CAS NO: 321432-05-7
• Molecular Formula: C₁₅H₁₃FO₃
• Molecular Weight: 260.26
• Mol File: 321432-05-7.mol

Chemical Properties

• Melting Point: 80-82°C
• Boiling Point: 397.4°C at 760 mmHg
• Flash Point: 187.4°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 1.59E-06mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE(321432-05-7)
• EPA Substance Registry System: 4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE(321432-05-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 321432-05-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE is used as a building block in organic synthesis for its ability to contribute to the formation of complex molecular structures. Its presence in reactions can lead to the development of new compounds with diverse applications.
Used in Pharmaceutical Research:
In Pharmaceutical Research, 4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE is used as a key component in the development of new drugs. Its unique structure allows it to be a part of molecules with potential therapeutic effects, contributing to advancements in medicinal chemistry.
Used in Drug Discovery:
4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE is utilized as a reagent in chemical reactions within the field of drug discovery. Its participation in these reactions may lead to the identification of novel drug candidates with improved pharmacological properties.
Used in Chemical Reactions:
In Chemical Reactions, 4-[(4-FLUOROBENZYL)OXY]-3-METHOXYBENZENECARBALDEHYDE is used for its potential to act as a reagent, facilitating various chemical processes that could result in the synthesis of new compounds with specific applications across different industries.

InChI:InChI=1/C15H13FO3/c1-18-15-8-12(9-17)4-7-14(15)19-10-11-2-5-13(16)6-3-11/h2-9H,10H2,1H3

Upstream product

• 121-33-5 vanillin 
• 459-46-1 4-Fluorobenzyl bromide 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 459-56-3 4-fluorobenzylic alcohol 

Downstream Products

• 883975-30-2 N-benzyl-1-{4-[(4-fluorobenzyl)oxy]-3-methoxyphenyl}methanamine 
• 880805-56-1 N-(4-(4-fluorobenzyloxy)-3-methoxybenzyl)-1-(pyridin-4-yl)methanamine 
• 1041563-49-8 C₁₅H₁₄ClFO₂ 

Relevant articles and documents

3-methyl pyridino-[1,2-a] pyrimidone derivative containing 1-((4-benzyl-substituted)oxygroup) and application

The invention discloses a 3-methyl pyridino-[1,2-a] pyrimidone derivative containing 1-((4-benzyl-substituted)oxygroup) and application. The general formula of the derivative is shown in the description, wherein R1 is a methoxyl group or an oxyethyl group or halogen; R2 is hydroxyl or isobutyl or ethyl or propyl or chloroethyl or 2-methoxyl group benzyl or 2-methoxyl group benzy or 2-fluorine benzyl or 2-cyanogroup benzyl chloride or 4-cyanogroup benzyl2-methyl benzyl chloride or 3-methyl benzyl chloride or 4-methyl benzyl chloride. According to the derivative, the rice bacterial leaf blight and citrus canker can be prevented and treated. The general formula is shown in the description.

First Discovery of Novel Pyrido[1,2- a]pyrimidinone Mesoionic Compounds as Antibacterial Agents

Plant bacterial diseases cause tremendous decreases in crop yield and quality, and there is a lack of highly effective and low-risk antibacterial agents. A series of novel pyrido[1,2-a]pyrimidinone mesoionic compounds containing vanillin moieties were synthesized, and the application of these mesoionic compounds as plant antibacterial agents was reported here for the first time. The bioassay results revealed that the mesoionic compounds had good antibacterial activity. Of these compounds, compound 11 showed excellent in vitro activity against Xanthomonas oryzae pv. oryzae, with an EC50 value of 1.1 μg/mL, which was substantially better than that of bismerthiazol (92.7 μg/mL) and thiodiazole copper (105.4 μg/mL). Moreover, greenhouse condition trials indicated that the protective and curative activities of compound 11 against rice bacterial leaf blight were 75.12 and 72.04%, respectively, which were better than those of bismerthiazol (62.24 and 50.83%, respectively) and thiodiazole copper (53.35 and 65.04%, respectively). These results provide a basis for the application of mesoionic vanillin moieties as new antibacterial agents.

Quinazoline derivatives as selective CYP1B1 inhibitors

CYP1B1 is implicated to have a role in the development of breast, ovarian, renal, skin and lung carcinomas. It has been suggested that identification of potent and specific CYP1B1 inhibitors can lead to a novel treatment of cancer. Flavonoids have a compact rigid skeleton which fit precisely within the binding cavity of CYP1B1. Systematic isosteric replacement of flavonoid ‘O’ atom with ‘N’ atom led to the prediction that a ‘quinazoline’ scaffold could be the basis for designing potential CYP1B1 inhibitors. A total of 20 quinazoline analogs were synthesized and screened for CYP1B1 and CYP1A1 inhibition in Sacchrosomes. IC50 determinations of six compounds with capability of inhibiting CYP1B1 identified quinazolines 5c and 5h as the best candidates for CYP1B1 inhibition, with IC50 values in the nM range. Further selectivity studies with homologous CYPs, belonging to the CYP1, CYP2 and CYP3 family of enzymes, showed that the compounds are likely to be free from critical drug-drug interaction liability. Molecular modelling studies were performed to rationalize the observed enzymatic inhibitions. Further biological studies in live yeast and human cells, harboring CYP1A1 and CYP1B1 enzymes, have illustrated the most potent compounds' cellular permeability and capability of potently inhibiting CYP1B1 enzyme expressed within live cells.

Facile Synthesis of Novel Vanillin Derivatives Incorporating a Bis(2-hydroxyethyl)dithhioacetal Moiety as Antiviral Agents

A series of vanillin derivatives incorporating a bis(2-hydroxyethyl)dithioacetal moiety was designed and synthesized via a facile method. A plausible reaction pathway was proposed and verified by computational studies. Bioassay results demonstrated that target compounds possessed good to excellent activities against potato virus Y (PVY) and cucumber mosaic virus (CMV), of which, compound 6f incorporating a bis(2-hydroxyethyl)dithioacetal moiety, exhibited the best curative and protection activities against PVY and CMV in vivo, with 50% effective concentration values of 217.6, 205.7 μg/mL and 206.3, 186.2 μg/mL, respectively, better than those of ribavirin (848.0, 808.1 μg/mL and 858.2, 766.5 μg/mL, respectively), dufulin (462.6, 454.8 μg/mL and 471.2, 465.4 μg/mL, respectively), and ningnanmycin (440.5, 425.3 μg/mL and 426.1, 405.3 μg/mL, respectively). Current studies provide support for the application of vanillin derivatives incorporating bis(2-hydroxyethyl)dithioacetal as new antiviral agents.

Vanillin-derived antiproliferative compounds influence Plk1 activity

We synthesized a series of vanillin-derived compounds and analyzed them in HeLa cells for their effects on the proliferation of cancer cells. The molecules are derivatives of the lead compound SBE13, a potent inhibitor of the inactive conformation of huma

Discovery of novel 3-benzylquinazolin-4(3H)-ones as potent vasodilative agents

In the present study, a series of 3-benzylquinazolin-4(3H)-ones were synthesized and characterized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with 60 mM KCl. The SAR of target compounds was discussed preliminarily. Among these compounds, 2a and 2c displayed potent vasodilatation action and could compete significantly the rat mesenteric arterial rings induced contraction with phenylephrine. Compounds 2a and 2c were further tested for their antihypertensive effects in SHR by oral administration. The results indicated that 2a and 2c could reduce significantly both diastolic and systolic blood pressure. Moreover, 2c displayed antihypertensive effect in a dose dependent manner, and could maintain the effects for 6 h at a dosage of 4.0 mg/kg. These findings suggest that the title compounds are novel vasodilative agents, representing a novel series of promising antihypertensive agents.

NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS

The present invention relates to the novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of metabolic disorders.

SUBSTITUDED BENZYLOXY-PHENYLMETHYLUREA DERIVATIVES

The present invention relates to novel substituted benzyloxy-phenylmethylurea derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol Receptor 1 (CMR

SUBSTITUTED 4-BENZYLOXY-PHENYLMETHYLAMIDE DERIVATIVES AS COLD MENTHOL RECEPTOR-1 (CMR-1) ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDER

The present invention relates to novel substituted benzyloxy-phenylmethylamide derivatives of formula (I), processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol